Global clinical trial for drug to treat Kala Azar to take place in 2021

News:Pharma major Novartis and the Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for Kala Azar. Facts: About Kala Azar: Kala-azar also known as Visceral leishmaniasis(VL) is caused by the protozoan parasite of genus Leishmania. It is spread to humans… Continue reading Global clinical trial for drug to treat Kala Azar to take place in 2021

A step closer to oral administration of kala-azar drug

Researchers from IIT Hyderabad have achieved a sustained release of a drug known as Amphotericin B for up to 10 days.This drug can be used for treating kala-azar. This will also help in oral administration of kala-azar drug which currently has major challenges. Visceral leishmaniasis(VL) also known as kala-azar is the most severe form of… Continue reading A step closer to oral administration of kala-azar drug